DD297560A5 - Schutzimpfstoff gegen schweine-haemophilose - Google Patents
Schutzimpfstoff gegen schweine-haemophilose Download PDFInfo
- Publication number
- DD297560A5 DD297560A5 DD90344141A DD34414190A DD297560A5 DD 297560 A5 DD297560 A5 DD 297560A5 DD 90344141 A DD90344141 A DD 90344141A DD 34414190 A DD34414190 A DD 34414190A DD 297560 A5 DD297560 A5 DD 297560A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- toxin
- serotype
- anatoxin
- pleuropneumoniae
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 41
- 230000001681 protective effect Effects 0.000 title claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 11
- 230000002949 hemolytic effect Effects 0.000 claims abstract description 11
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims abstract description 9
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 8
- 239000003053 toxin Substances 0.000 claims description 33
- 231100000765 toxin Toxicity 0.000 claims description 33
- SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 claims description 28
- 239000003948 anatoxin Substances 0.000 claims description 28
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 241000606750 Actinobacillus Species 0.000 claims description 3
- 230000003389 potentiating effect Effects 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 4
- 229910052791 calcium Inorganic materials 0.000 claims 4
- 239000011575 calcium Substances 0.000 claims 4
- 230000006798 recombination Effects 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 108700012359 toxins Proteins 0.000 description 24
- 239000002609 medium Substances 0.000 description 10
- 241000282887 Suidae Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000006509 pleuropneumonia Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 101710179002 Hemolytic toxin Proteins 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR898912567A FR2652266B1 (fr) | 1989-09-26 | 1989-09-26 | Vaccin protecteur contre l'hemophilose porcine. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD297560A5 true DD297560A5 (de) | 1992-01-16 |
Family
ID=9385815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD90344141A DD297560A5 (de) | 1989-09-26 | 1990-09-21 | Schutzimpfstoff gegen schweine-haemophilose |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0420743B1 (da) |
| JP (1) | JP3169379B2 (da) |
| AT (1) | ATE189609T1 (da) |
| AU (1) | AU635349B2 (da) |
| CA (1) | CA2035474C (da) |
| DD (1) | DD297560A5 (da) |
| DE (2) | DE10199019I1 (da) |
| DK (1) | DK0420743T3 (da) |
| ES (1) | ES2143456T3 (da) |
| FR (1) | FR2652266B1 (da) |
| GR (1) | GR3033151T3 (da) |
| PT (1) | PT95396B (da) |
| WO (1) | WO1991004747A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5417971A (en) * | 1991-10-22 | 1995-05-23 | University Of Saskatchewan | Vaccines for Actinobacillus pleuropneumoniae |
| CA2170839A1 (en) * | 1995-03-01 | 1996-09-02 | Janet Macinnes | Bacterial preparations, method for producing same, and their use as vaccines |
| US5925354A (en) * | 1995-11-30 | 1999-07-20 | Michigan State University | Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK138379A (da) * | 1979-04-04 | 1980-10-05 | Nordisk Droge & Kemikalie | Vaccine imod pleuropneumonia (ondartet lungesyge) hos svin dens anvendelse samt fremgangsmaade og substat til dyrkning specielt aerob fermentering af mikroorganismen haemophilus pleuropneumoniae |
| IE59079B1 (en) * | 1986-11-05 | 1994-01-12 | Oldcastle Veterinary Research | A method of preparing an autogenous vaccine |
-
1989
- 1989-09-26 FR FR898912567A patent/FR2652266B1/fr not_active Expired - Lifetime
-
1990
- 1990-09-21 DD DD90344141A patent/DD297560A5/de unknown
- 1990-09-24 PT PT95396A patent/PT95396B/pt not_active IP Right Cessation
- 1990-09-25 EP EP90402639A patent/EP0420743B1/fr not_active Expired - Lifetime
- 1990-09-25 AT AT90402639T patent/ATE189609T1/de not_active IP Right Cessation
- 1990-09-25 DE DE2001199019 patent/DE10199019I1/de active Pending
- 1990-09-25 AU AU65230/90A patent/AU635349B2/en not_active Expired
- 1990-09-25 JP JP51391990A patent/JP3169379B2/ja not_active Expired - Lifetime
- 1990-09-25 ES ES90402639T patent/ES2143456T3/es not_active Expired - Lifetime
- 1990-09-25 CA CA002035474A patent/CA2035474C/en not_active Expired - Lifetime
- 1990-09-25 DE DE69033454T patent/DE69033454T2/de not_active Expired - Lifetime
- 1990-09-25 WO PCT/FR1990/000688 patent/WO1991004747A1/fr not_active Ceased
- 1990-09-25 DK DK90402639T patent/DK0420743T3/da active
-
2000
- 2000-04-04 GR GR20000400844T patent/GR3033151T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2035474A1 (en) | 1991-03-27 |
| ATE189609T1 (de) | 2000-02-15 |
| PT95396A (pt) | 1991-05-22 |
| ES2143456T3 (es) | 2000-05-16 |
| DK0420743T3 (da) | 2000-06-19 |
| EP0420743A1 (fr) | 1991-04-03 |
| DE10199019I1 (de) | 2001-05-23 |
| FR2652266B1 (fr) | 1994-08-12 |
| WO1991004747A1 (fr) | 1991-04-18 |
| GR3033151T3 (en) | 2000-08-31 |
| JPH04502018A (ja) | 1992-04-09 |
| DE69033454D1 (de) | 2000-03-16 |
| PT95396B (pt) | 1997-07-31 |
| AU635349B2 (en) | 1993-03-18 |
| JP3169379B2 (ja) | 2001-05-21 |
| EP0420743B1 (fr) | 2000-02-09 |
| DE69033454T2 (de) | 2000-06-21 |
| AU6523090A (en) | 1991-04-28 |
| FR2652266A1 (fr) | 1991-03-29 |
| CA2035474C (en) | 2002-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69033600T2 (de) | Verfahren zur Isolierung von Haemopnilus influenzae Protein-E | |
| DE68928432T2 (de) | Legionellosis-impfstoffe und verfahren zur herstellung | |
| DE69519634T2 (de) | Pneumokokken-polysaccharid-rekombinante-pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen | |
| DE69515613T2 (de) | Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa | |
| DE69110082T2 (de) | Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae. | |
| DE69419966T2 (de) | Impstoff gegen Streptococcus suis-Infektion | |
| DE69212459T2 (de) | Impfstoff gegen infektionen durch neisseria meningitidis | |
| JPH0840932A (ja) | スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法 | |
| DE69836744T2 (de) | Gruppe a streptokokken-impfstoff | |
| DE3882781T2 (de) | Impfstoff gegen Pasteurella. | |
| DE69735856T2 (de) | Il-12 als adjuvanz für bordetella pertussis impfstoffe | |
| DE3686158T2 (de) | Impfstoff gegen mastitis. | |
| DE69535422T2 (de) | Vakzin für einen nicht typisierbaren Haemophilus influenzae Stamm | |
| DE69434000T2 (de) | Impfstoffzusammensetzungen | |
| DE69631543T2 (de) | Immunität gegen pasteurella haemolytica leukotoxin | |
| US4293545A (en) | Modified Pasteurella multocida bacteria vaccines | |
| US4328210A (en) | Modified Pasteurella bacteria and vaccines prepared therefrom | |
| DE69227984T2 (de) | Impfstoff, der eine Untereinheit des menschlichen Transferrin-Rezeptors von Neisseria meningitidis enthält | |
| DE69531186T2 (de) | Antibordetella azellulärer Impfstoff | |
| DE69329494T2 (de) | Fusobacterium necrophorum leukotoxoid vakzin | |
| DD297560A5 (de) | Schutzimpfstoff gegen schweine-haemophilose | |
| US5176910A (en) | Treponema hyodysenteriae hemolysin and uses therefor | |
| WO2000075345A1 (de) | Rekombinantes fusionsprotein, dieses enthaltende (impf-)stoffzusammensetzung und verfahren zu dessen herstellung | |
| US4335106A (en) | Processes for the growth of a modified Pasteurella multocida bacteria and preparation of a vaccine therefrom | |
| DE69531690T2 (de) | Reinigungsverfahren für von bordetella bronchiseptica produziertes dermonekrotisches toxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RPI | Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act) | ||
| ASS | Change of applicant or owner |
Owner name: MERIAL SAS, LYON Effective date: 19980825 |
|
| IF04 | In force in the year 2004 |
Expiry date: 20100922 |